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Abstract
Background: Vaccination with Mycobacterium bovis bacille Calmette-Gue ´rin (BCG) is widely used to reduce the risk of
childhood tuberculosis and has been reported to have efficacy against two other mycobacterial diseases, leprosy and Buruli
ulcer caused by M. ulcerans (Mu). Studies in experimental models have also shown some efficacy against infection caused by
Mu. In mice, most studies use the C57BL/6 strain that is known to develop good cell-mediated protective immunity. We
hypothesized that there may be differences in vaccination efficacy between C57BL/6 and the less resistant BALB/c strain.
Methods: We evaluated BCG vaccine efficacy against challenge with ,3610
5 M. ulcerans in the right hind footpad using
three strains: initially, the Australian type strain, designated Mu1617, then, a Malaysian strain, Mu1615, and a recent
Ghanaian isolate, Mu1059. The latter two strains both produce mycolactone while the Australian strain has lost that
capacity. CFU of both BCG and Mu and splenocyte cytokine production were determined at intervals after infection. Time to
footpad swelling was assessed weekly.
Principal Findings: BCG injection induced visible scars in 95.5% of BALB/c mice but only 43.4% of C57BL/6 mice. BCG
persisted at higher levels in spleens of BALB/c than C57BL/6 mice. Vaccination delayed swelling and reduced Mu CFU in
BALB/c mice, regardless of challenge strain. However, vaccination was only protective against Mu1615 and Mu1617 in
C57BL/6 mice. Possible correlates of the better protection of BALB/c mice included 1) the near universal development of
BCG scars in these mice compared to less frequent and smaller scars observed in C57BL/6 mice and 2) the induction of
sustained cytokine, e.g., IL17, production as detected in the spleens of BALB/c mice whereas cytokine production was
significantly reduced, e.g., IL17, or transient, e.g., Ifnc, in the spleens of C57BL/6 mice.
Conclusions: The efficacy of BCG against M. ulcerans, in particular, and possibly mycobacteria in general, may vary due to
differences in both host and pathogen.
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Introduction
BCG vaccination is widely practiced around the world,
primarily to protect against tuberculosis. BCG is a safe vaccine
but its efficacy against tuberculosis varies by geographical region
and possibly by BCG strain due to mutations related to culturing
practices in multiple laboratories for many decades. The current
consensus is that it protects against disseminated tuberculosis in
young children but that it has limited value in protecting against
adult pulmonary tuberculosis, perhaps affording 50% protection at
best [1]. On the other hand, large trials [2] have shown that even
where BCG has no discernible benefit against tuberculosis, it does
protect against leprosy, a disease caused by another mycobacte-
rium, M. leprae. Against yet another mycobacterial disease, known
as Mycobacterium ulcerans disease or Buruli Ulcer (BU), retrospective
and prospective studies have found that BCG vaccination appears
to have protective efficacy for only up to 6 months but there may
be longer term protection against severe forms of BU, such as
osteomyelitis [3,4,5,6,7]. A case report indicated that the Th1 type
immunity following BCG vaccination changed to a Th2 type after
the onset of BU [8,9]. Our preliminary investigation of a toxin-
negative Mu strain and studies by others suggested differences in
host response between C57BL/6 and BALB/c mice [10,11,12],
and therefore, studies in mice might help identify the timing and
nature of the switch and allow testing of alternative ways to
maintain protective immunity.
Mycobacterium ulcerans disease was first described in the medical
literature in 1948 in Australian patients [13]. The disease still
occurs there, primarily in coastal areas visited by vacationers. In
contrast, many more cases have been documented to occur in
Africa, initially in the Congo [14] and Uganda [15], and then,
increasingly in West Africa where it primarily affects impoverished
people in rural riverine and swampy areas [16,17,18]. The exact
mode of transmission is controversial. Bug bites are frequently but
not universally recalled. M. ulcerans grows slowly at ,30–32 uC. It
was the first mycobacterium shown to produce a toxin, an
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Toxin-producing colonies have a yellowish color. The toxin is
encoded by the pksA gene, located on a giant plasmid [22,23,24].
The toxin destroys subcutaneous fat cells, apparently by both
apoptotic and necrotic mechanisms [25,26,27]. Both guinea pigs
and mice have been used to model the disease and study the
organism [21,28,29,30]. In mice injected in the hind footpad,
there is gradual, infection-dose-dependent swelling that becomes
severe before the onset of ulceration and, if allowed, may progress
to foot and limb loss and death [31,32].
Here, we vaccinated BALB/c and C57BL/6 mice with BCG
(Pasteur) and, after 8 weeks, challenged vaccinated and unvacci-
nated mice with either M. ulcerans 1059 (Mu1059), a recent clinical
isolate from Ghana, or with Mu1615, a strain originally isolated
from Malaysia in the 1960s. Both strains produce mycolactone
and both cause a gradually severe swelling in mouse footpads in
unvaccinated mice.
Materials and Methods
Bacteria
M. ulcerans 1059 (Mu1059, a recent clinical isolate from Ghana)
and M. ulcerans 1615 (Mu1615, an isolate originally obtained from a
patient in Malaysia in the 1960s, [33] were kindly provided by Dr.
Pamela Small, University of Tennessee. M. ulcerans 1617 (Mu1617,
the typestrainisolated from a patientin Australia in the 1940s,[13])
was obtained from the American Type Culture Collection (ATCC,
Manassas, VA). Thin layer chromatographic analysis and cytotox-
icity assays of ethanolic extracts showed that Mu1059 and Mu1615,
but not Mu1617, produce mycolactone and kill macrophages and
fibroblasts ([34], and see Fig. S3). All three strains were passaged in
mouse footpads before use in these studies. The bacilli were
harvested from swollen footpads at the grade 3 level, i.e., swelling
with inflammation of the footpad and leg [35].
BCG Vaccination
Female BALB/c and C57BL/6 mice, aged 4–6 weeks, obtained
from Charles River (Wilmington, MA), were vaccinated subcuta-
neously with 5.8610
4 CFU of M. bovis BCG, Pasteur strain, in
0.2 ml or with the diluent (Middlebrook 7H9, also 0.2 ml) as a
sham manipulation, 8 weeks before challenge with M. ulcerans.
Challenge and CFU analysis
Mice were inoculated in the right hind footpad with
approximately 3610
5 in 0.03 ml of Mu1059, Mu1615, or
Mu1617. At different time points after challenge, mice were
sacrificed and footpad tissue was harvested, minced with fine
scissors [36], suspended in 2.0 ml PBS, serially diluted, and plated
for CFU analysis on Middlebrook selective 7H11 plates (Becton-
Dickinson, Sparks, MD). Mice were evaluated for footpad swelling
weekly using an established scoring system [35] with grade 1
showing footpad swelling, grade 2 swelling with inflammation, and
grade 3 swelling and inflammation of the entire foot [32]. Time to
grade 1 swelling was assessed by Kaplan-Meier analysis. All
animal procedures were conducted according to relevant national
and international guidelines. The study was conducted adhering to
the Johns Hopkins University guidelines for animal husbandry and
was approved by the Johns Hopkins Animal Care and Use
Committee, protocols MO08M240 and MO05M226.
Splenocyte assays
After BCG or sham vaccination, spleens were harvested from
mice, placed in 2.5 ml RPMI 1640 (Mediatech, Herndon, VA)
and passed through a 70 mm cell strainer (BD Falcon 352350) into
a centrifuge tube. From the suspension, 120 ml was added to
1.88 ml of RPMI containing 5% fetal bovine serum and 1%
penicillin (100 U/ml) and streptomycin (100 mg/ml). From this
suspension 100 ml was added to triplicate wells of a 96 well plate
(Costar 3595, Corning, NY) containing 10 ml of culture filtrate
protein of Mtb H37Rv (CFP, [10 mg/ml]) or Mtb antigen 85
(Ag85), also at 10 mg/ml, both supplied by Colorado State
University TB Vaccine Testing and Research Materials Contract
(NIH-NIAID N01-AI-40091), or with Concanavalin A (ConA,
Sigma, [2 mg/ml]). The cells were incubated at 37 uC for 48 hours
before harvesting, pooling, and freezing at 270 uC of triplicate 50
ml supernatants. The remainder of the suspension was used to
enumerate BCG CFU.
Cytokine assays
A 23-plex Luminex assay (Biorad, Hercules, CA) was used to
detect 4 Th1 (IL2, IL12b/p40, IL12p70, and Ifnc), 4 Th2 (IL4,
IL5, IL10, and IL13), and 4 proinflammatory cytokines (IL1a,
IL1b, IL6, and Tnfa) as well as IL17, IL9, 6 chemokines (Cxcl1,
Ccl2, Ccl3, Ccl4, Ccl5, and Ccl11), and 3 colony stimulating
factors (IL3, Csf2, and Csf3). Using aliquots from the same
supernatants, Tgfb was detected using Milliplex beads (Millipore,
Billerica, MA).
Statistical analysis
Comparisons were made by the log-rank test for time-to-grade 1
swelling and by 2-way ANOVA for log10 transformed CFU counts
and cytokine levels.
Results
BCG vaccination produces scars more frequently in BALB/
c than in C57BL/6 mice
Nearly all BALB/c mice developed visible scars at the site of
vaccination in the flank (Fig. 1) but such scars occurred less
frequently and were smaller in C57BL/6 mice. This observation
was assessed and noted for each mouse 13 weeks after vaccination
Author Summary
Vaccination with Mycobacterium bovis bacille Calmette-
Gue ´rin (BCG) is used to reduce the risk of childhood
tuberculosis and is reported to have efficacy against two
other diseases also caused by mycobacteria, leprosy and
Buruli ulcer caused by M. ulcerans. We hypothesized that
there may be differences in the effectiveness of BCG
vaccination in different mouse strains. We vaccinated two
mouse strains with BCG eight weeks before infection with
three different strains of M. ulcerans. Two of the bacterial
strains make a toxin that is critical for Buruli ulcer disease
and the third does not. We observed the progression of
disease in vaccinated and mock-vaccinated mice and also
evaluated the immune response of the mice. We found
that the BALB/c mice respond to BCG vaccination with
prominent scars, a vigorous immune response, and
delayed or no manifestations of M. ulcerans infection.
C57BL/6 mice, on the other hand, usually do not have
vaccination scars, make a relatively short-lived and/or
weaker immune response, and all show disease at the site
of M. ulcerans infection. We conclude that the efficacy of
BCG against M. ulcerans, and possibly other diseases,
depends on the nature of the host and of the infecting
strain of the bacteria.
BCG Vaccination and Murine Buruli Ulcer
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mice but only 43.4% of C57BL/6 mice had scars after BCG
vaccination. No sham-vaccinated mice had scars.
After subcutaneous vaccination, BCG multiplies in spleen
and survives longer in BALB/c mice
C57BL/6 mice are considered to be more resistant than BALB/
c mice to intracellular infections with mycobacteria or leishmania
species [37,38]. Consistent with these observations we found that
after subcutaneous M. bovis BCG vaccination, BALB/c mice have
higher levels of BCG detectable in the spleen than do C57BL/6
mice (Fig. 2 A, B, C). In addition, the levels persisted longer in
BALB/c mice. The number of BCG CFU in the spleen tended to
be higher in M. ulcerans-challenged C57BL/6 compared to
unchallenged mice (Fig. 2 B and C) whereas there was no
difference between challenged and unchallenged BALB/c mice.
M. ulcerans infection is established at comparable levels
in BALB/c and C57BL/6 mice with all 3 bacterial strains
Mice were inoculated with freshly isolated suspensions contain-
ing ,10 AFB/high-power microscopic field or 2.4–3610
5 M.
ulcerans in a volume of ,0.03 ml in the right hind footpad,
resulting in an implantation of ,3.1–3.2 log10 of the Australian
type strain, Mu1617 on day 1 (Fig. 3A). As reported by others (e.g.,
[39]) there is a lag phase with little or no increase in CFU during
the first 2 weeks after challenge, followed by a logarithmic increase
accompanied by footpad swelling by week 5 to 6 when the CFU
counts reach 10
5 or higher. For example at week 2 after infection,
we detected from ,3–3.5 log10 M. ulcerans CFU in the mouse
footpads infected with Mu1059 or Mu1615, independent of BCG
vaccination status (data not shown).
Figure 1. After subcutaneous vaccination with BCG-Pasteur,
BALB/c mice consistently have visible scars. Scars were less
frequently seen in C57BL/6 mice and tended to be smaller. The pictured
mouse was vaccinated 10 weeks previously and had been challenged
with M. ulcerans 2 weeks previously in the right hind footpad.
doi:10.1371/journal.pntd.0000985.g001
Figure 2. After subcutaneous vaccination BCG persists in spleen longer in BALB/c than in C57BL/6 mice. Variability is greater in the
C57BL/6 mice. At week 8, mice were challenged with M. ulcerans. By week 25, no BCG colonies could be detected in the C57BL/6 mice (A, C). (N=3,
except at week 25 where N=2; one of two comparable experiments shown). At week 14 (B), BCG CFU appeared to be higher in C57BL/6 mice
challenged with M. ulcerans. (C) The one C57BL/6 mouse available at week 25 after vaccination and 17 weeks after M. ulcerans challenge did have
detectable BCG in the spleen.
doi:10.1371/journal.pntd.0000985.g002
BCG Vaccination and Murine Buruli Ulcer
www.plosntds.org 3 March 2011 | Volume 5 | Issue 3 | e985BCG vaccination prevents multiplication of M. ulcerans
better in BALB/c than in C57BL/6 mice
At week 6, after the onset of swelling in the sham-vaccinated
mice, marked differences in M. ulcerans CFU counts were observed
between BCG-vaccinated and unvaccinated (i.e., sham) BALB/c
mice regardless of the infecting M. ulcerans strain (Mu1617,
p,0.01, Mu 1059, p,0.001, or Mu1615, p,0.001, Figure 3). In
C57BL/6 mice BCG vaccination did not result in a reduction in
Mu1617 (Fig. 3A) or Mu1059 CFU (Fig. 3B) but did lead to a
significant (p,0.01) reduction in M. ulcerans 1615 CFU (Fig. 3C) in
the footpads of mice.
BCG vaccination delays time to footpad swelling in a M.
ulcerans strain- and mouse strain-dependent manner
In unvaccinated BALB/c and C57BL/6 mice, the median time
to grade 1 or higher footpad swelling was ,5–6 weeks following
infection with either of the toxin-producing strains (Fig. 4A and
4B) whereas it was 6.5 weeks in C57BL/6 mice and 16 weeks in
BALB/c mice infected with the non-toxin-producing Mu1617
strain (Fig. 4C). All unvaccinated BALB/c and C57BL/6 mice
developed footpad swelling except for 37% of BALB/c mice
challenged with the Mu1617 strain.
In BCG vaccinated BALB/c mice, the median time to swelling
was .26 weeks in mice challenged with the Mu1059 Ghanaian
strain (Fig. 4A) and 14 weeks with the Mu1615 Malaysian strain
(Fig. 4B). Only 23% of vaccinated BALB/c mice developed
swelling by week 36 after infection with the toxin free, Mu1617
Australian strain (Fig. 4C). Remarkably, approximately 25%, 50,
or 75% of, vaccinated BALB/c mice infected with Mu1615,
Mu1059, and Mu1617, respectively, never developed swelling. In
addition, some appeared to self-heal with a regression of the
swelling.
In contrast, the effect of BCG vaccination on median time to
swelling in C57BL/6 mice varied from a delay of only 1 week in
mice challenged with the Mu1059 strain (Fig. 4A) to a delay of 7
weeks in mice challenged with the Mu1615 and Mu1617 strains
(Fig. 4B and 4C). All vaccinated C57BL/6 mice eventually
developed swelling regardless of the challenge strain. Taken
together, these results suggest that vaccine efficacy varies
according to both the mouse strain and the M. ulcerans strain that
were tested.
BCG vaccine efficacy correlates with BCG scar formation
and with sustained cytokine production in response to
mycobacterial antigens
At different times after vaccination, splenocytes were assessed
for the ability to produce cytokines after restimulation with CFP or
Ag85 of Mtb as well as Concanavalin A. The responses to Ag85
correlated very well with those to CFP. Because we tested more
time points with CFP, we report, for the sake of simplicity, only
those results. Similar results for cytokine production were observed
after challenge with either Mu1615 or Mu1059 and, therefore,
those data are combined.
Proinflammatory cytokines. The proinflammatory cyto-
kines IL1a and IL1b were produced at identical levels and rates
over the first 3 weeks after BCG vaccination in both mouse strains.
Thereafter, production increased markedly in BALB/c but
decreased in C57BL/6 mice at week 7. Production declined
after challenge with M. ulcerans in both mouse strains when tested 8
weeks after BCG vaccination and one week after challenge. Two
weeks after challenge, IL1 could not be detected in supernatants of
C57BL/6 splenocytes stimulated with CFP (Fig. S1). The same
pattern was observed for Tnfa (Fig. 5 A) and IL6 (Fig. 5E), except
that the former was somewhat higher in C57BL/6 mice and the
Figure 3. M. ulcerans infection is established comparably in BALB/c and C57BL/6 mice. A) CFU counts of the Mu1617 strain of M. ulcerans
are comparable between C57BL/6 and BALB/c mice and with the mycolactone-producing Ghanaian strain, Mu1059 (not shown) regardless of BCG
vaccination status. M. ulcerans CFU at day 28 are significantly lower in vaccinated BALB/c mice (**, p,0.01). B) and C): Mice that show a protective
response to BCG vaccination have reduced M. ulcerans CFU after the onset of swelling (week 5 or 6) in unprotected, i.e., unvaccinated, mice.
doi:10.1371/journal.pntd.0000985.g003
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extent, in C57BL/6 mice after BCG vaccination. BCG-mediated protection against swelling was greatest in BALB/c mice, regardless of M.
ulcerans strain. Significant protection was also observed in C57BL/6 mice against the toxin-producing Malaysian strain, Mu1615 (B), and the non-
toxin-producing Australian type strain, Mu1617 (C), but negligible protection was observed with the Ghanaian strain, Mu1059 (A). It is noteworthy
that swelling occurred after infection with the non-toxin-producing Mu1617 strain (C) but that the onset of swelling was delayed even in
unvaccinated BALB/c mice.
doi:10.1371/journal.pntd.0000985.g004
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not statistically significant.
Th1 cytokines. The same kinetics of expression was observed
for Th1 cytokines Ifnc, IL2, IL12b, and IL12 p70 (Fig. S1). The
peak at week 3 was higher for Ifnc (Fig. 5B) and IL12b in C57BL/
6 than in BALB/c mice; however, the differences were not
statistically significant by 2-way ANOVA. IL12p70 was
undetectable in C57BL/6 mice even before M. ulcerans
challenge. Both Ifnc and IL12p70 were undetectable 2 weeks
after M. ulcerans challenge in both mouse strains.
Th2 cytokines. Again the same kinetics pattern of sustained
cytokine production in BALB/c mice but a peak in production at
week 3 in C57BL/6 mice was observed for the Th2 cytokines IL4
(Fig. 5C), IL5, IL10, and IL13 (Fig. S1).
Th17 cytokines. The pattern and the level of IL17 (Fig. 5D)
production in response to CFP were markedly different between
the two mouse strains. At week 3 the mean IL17 concentrations, in
pg/ml, were 84641 (range, 40–166) for BALB/c mice but 1366
(range, 3–21) for C57BL/6 mice. At week 7 the concentrations
were 27036487 for BALB/c mice and 2669 for C57BL/6 mice.
After M. ulcerans challenge, IL17 was almost undetectable one
week later in C57BL/6 mice whereas in BALB/c mice levels only
declined to 7056203 and 67613 in the two weeks after challenge.
Among the factors required for the generation of Th17cells are
IL6 and Tgfb. As noted above, IL6 (Fig. 5E) levels were initially
somewhat, though not significantly, higher in BALB/c than in
C57BL/6 mice and, as with other cytokines, continued to increase
in the BALB/c mice while declining in the C57BL/6 mice. The
pattern for Tgfb (Fig. 5F) was different from the other cytokines.
Values were 2.5-fold higher at day 1, 3.2-fold lower at 3 weeks but
again slightly higher at 7 weeks in BALB/c mice compared to
C57BL/6 mice, although the differences were not statistically
different. Tgfb values also remained higher after M. ulcerans
challenge in BALB/c mice but dropped precipitously in C57BL/6
mice. The results for Tgfb could be consistent with the cytokine
helping to drive, through the Rorct transcription factor, a Th17
response in BALB/c mice while inducing a regulatory T cell (Treg)
response, through the Foxp3 transcription factor, in C57BL/6
mice in which cytokine production was consistently down
modulated after week 3. Taken together, the data suggest that
the strong IL17 response in BALB/c mice compared to C57BL/6
mice correlates with BCG vaccine-mediated protection against M.
ulcerans-induced footpad swelling and the reduction in M. ulcerans
CFU detectable in BALB/c footpads.
Figure 5. Cytokine production in spleens of BCG-vaccinated C57BL/6 and BALB/c mice before and after challenge with M. ulcerans
strains Mu1615 and Mu1059. Representative proinflammatory (A), Th1 (B), and Th2 (C) cytokines are shown. IL17 production is shown in Panel D.
IL6, required for the generation of Th17 cells, is shown in panel E. Tgfb, required for the generation of both Th17 and regulatory T (Treg) cells,
production is shown in panel F. Graphs of other cytokines (Fig. S1) and also chemokines (Fig. S2) are available in Supplementary Materials.
doi:10.1371/journal.pntd.0000985.g005
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10 chemokines in Fig. S2.
Discussion
BCG vaccination protects BALB/c mice better than C57BL/6
mice from the consequences of M. ulcerans infection. In the case of
infection with the Mu1059 isolate from Ghana, C57BL/6 mice
were essentially not protected at all whereas most BALB/c
remained swelling free. In general, BALB/c mice make a stronger
and more sustained cytokine response than do C57BL/6 mice.
The most salient difference in cytokine production between the
two mouse strains was the IL17 response. IL17 is known to be
associated with protection against extracellular fungi and bacteria
[40].
Others have also observed differential production of IL17
between C57BL/6 and BALB/c mouse strains [38]. In contrast to
our findings of an association between high levels of IL17 and
BCG-induced protection from M. ulcerans disease, Lopez Kostka
found that BALB/c mice produced ‘‘excessive’’ levels of IL17, as
well as Th2 cytokines, and are more susceptible to cutaneous
leishmaniasis after infection with L. major [38]. In the leishmania
model, C57BL/6 mice have a strong Th1 response but produce
little IL17. In this model, killing of the organism occurs following
Ifnc production and macrophage activation with elaboration of
nitric oxide. BCG, on the other hand, induces granuloma
formation that may help contain mycobacteria. Very recently,
Okamoto Yoshida et al. reported that mice lacking IL17, in a
C57BL/6 background, fail to produce granulomas after pulmo-
nary BCG infection [41]. Whether subcutaneous BCG vaccination
promotes granuloma formation in footpads and protection against
M. ulcerans infection requires further investigation.
Our findings in BALB/c mice are consistent with those of
Coutanceau et al. [10] who also observed a .3 log10 reduction in
Mu1615 CFU at the site of infection in mice vaccinated
subcutaneously with BCG Pasteur (Fig. 3C). The results here
extend the data to C57BL/6 mice in which there was also a 3.26
log10 reduction in Mu1615 CFU at 6 weeks after challenge. An
earlier study [12] found that in intravenously BCG-vaccinated
C57BL/6 mice challenged with M. ulcerans strain 5150 from the
Congo, there was only a 1.35–1.85 log10 reduction in the footpad
CFU counts 7 weeks after challenge. We likewise saw a reduction
of only 0.88 log10 CFU in vaccinated C57BL/6 mice challenged
with the Ghanaian Mu1059 strain. However, vaccinated BALB/c
mice challenged with Mu1059 showed a 4.32 log10 reduction in
CFU. These data strongly support the idea that there are host
differences in the ability to be protected by BCG from M. ulcerans
infection as well as marked differences in the protection conferred
against different strains of M. ulcerans.
In addition to counting M. ulcerans CFU, we assessed the ability
of BCG vaccination to prevent footpad swelling, a clinically
observable consequence of M. ulcerans infection in mice. BCG
vaccination delayed the onset of footpad swelling in both BALB/c
and C57BL/6 mice. However, the delay was greater in BALB/c
mice, regardless of the challenge strain and C57BL/6 mice
showed only a 1-week delay in swelling when challenged with the
Ghanaian Mu1059 strain. These findings support the differences
found in CFU and also tend to confirm the difference in host
susceptibility to M. ulcerans noted parenthetically by others [10].
Differential susceptibility to mycobacterial infection in mice has
been the subject of numerous studies. BALB/c and C57BL/6 mice
have very similar survival rates after aerosol infection with M.
tuberculosis. Both strains are markedly resistant compared to CBA,
DBA/2, C3H, and 129/SvJ when challenged by the intravenous
or aerosol routes. Interestingly, the distinction was overcome by
increasing the i.v. challenge dose [42]. This study was followed up
by evaluating the ability of BCG vaccination to protect BALB/c
and DBA/2 (both having the same MHC type) against an
intravenous challenge with M. tuberculosis. For both strains there
was a ,10-fold reduction in the number of CFU in the lung 80
days after challenge. However, at this time, there was also a 100-
fold difference in the number of CFU in the lungs of the
immunized BALB/c and DBA/2 mice. In addition, the DBA/2
mice also had extensive necrotic lesions whereas the BALB/c
lesions were more compact and epithelioid like [43]. Similar
findings were obtained when comparing vaccinated C57BL/6
mice and the susceptible strains, DBA/2 and CBA/J [44]. Other
studies have linked differential susceptibility to matrix metallopro-
teinases such as Mmp9 [45]. Hence, the finding of a difference in
the susceptibility of different mouse strains to mycobacteria is not
novel but the difference in susceptibility of BALB/c and C57BL/6
mice, both resistant to M. tuberculosis,t oM. ulcerans has not been
shown before nor, to our knowledge, has the difference in the
ability of BCG vaccination to protect these different mouse strains
been examined before.
The importance of IL17 may be due to the fact that the
intracellular phase is relatively brief after M. ulcerans infection due
to toxin-mediated killing of phagocytic cells whereas, in mice, M.
tuberculosis infection remains intracellular throughout the course of
infection (unpublished observations and [46]). Studies in progress
indicate that at week 2 after infection with a mycolactone-
producing strain, Mu1615, the organisms are still largely
intracellular. By week 3, the infection is predominantly extracel-
lular in BALB/c mice, presumably due to the destruction of
phagocytes by mycolactone. BCG vaccination may promote IL17
production, particularly in this mouse strain, and enable resistance
against extracellular organisms. In contrast, C57BL/6 mice,
infected with Mu1617, which does not produce mycolactone,
have abundant organisms that appear to be intracellular, even at 4
weeks after infection.
The results of this study suggest that vaccination with BCG may
protect some hosts more effectively than others against M. ulcerans
infection or disease. In addition, the protection may depend on the
strain of M. ulcerans prevalent in a given community. While the
benefit of BCG vaccination may be variable, we also found no
evidence of vaccination leading to exacerbated disease in this
model.
Supporting Information
Figure S1 Proinflammatory, Th1, and Th2 cytokine production
after BCG vaccination before and after M. ulcerans challenge.
Found at: doi:10.1371/journal.pntd.0000985.s001 (0.04 MB
DOC)
Figure S2 Chemokine production after BCG vaccination before
and after M. ulcerans challenge.
Found at: doi:10.1371/journal.pntd.0000985.s002 (0.03 MB
DOC)
Figure S3 Thin layer chromatography analysis shows that the
Ghanaian (Mu1059) and Malaysian (Mu1615) strain produce
mycolactone, but the Australian type strain (Mu1617) does not.
Found at: doi:10.1371/journal.pntd.0000985.s003 (4.46 MB TIF)
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